Pulmonary drugs Flashcards
Albuterol
beta 2 agonist short acting ^ cAMP causes bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tachycardia, tremors, transient dec. in K levels, lactic acidosis USES: acute asthma exacerbation, exercise induced asthma, acute COPD
Levalbuterol
beta 2 agonist short acting ^ cAMP causes bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tremors, tachycardia, transient dec. in K levels, lactic acidosis USES: acute asthma exacerbation, exercise induced asthma, acute COPD
Terabutaline
beta 2 agonist short acting ^ cAMP causes bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tachycardia, tremors, transient dec. in K levels, lactic acidosis USES: acute asthma exacerbation, exercise induced asthma, acute COPD
Formoterol
beta 2 agonist long acting ^cAMP causes bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tachycardia, tremor, lactic acidosis, transient dec. in K levels Must be combined with ICS to prevent increased risk of asthma related death USES: prevention of asthma attack, COPD maintenance
Salmeterol
beta 2 agonist long acting ^cAMP causes bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tachycardia, tremors, transient dec. in K levels, lactic acidosis must be combined with ICS to prevent increased risk of asthma related deaths USES: prevention of asthma attacks; maintenance of COPD
Indacaterol
beta 2 agonist long acting ^cAMP causes bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tachycardia, tremors, transient dec. in K levels, lactic acidosis Must be given with ICS to prevent increased risk of asthma related deaths USES: prevention of asthma attacks; maintenance of COPD
Vilanterol
beta 2 agonist long acting ^ cAMP results in bronchodilation, mast cell stabilization, and skeletal muscle stimulation ADR: tachycardia, tremors, transient dec. in K levels, lactic acidosis Must be given with ICS to prevent increased risk of asthma related deaths USES: prevention of asthma attacks; maintenance of COPD
Ipratropium Bromide
anticholinergic short acting inhibits M1 and M3 which results in dec. cGMP –> bronchodilation ADR: blurred vision, dry mouth, nausea, urinary retention, tachycardia, CNS effects (low bioavailibility so minimal side effects) USES: acute asthma, acute COPD, maintenance of COPD bronchospasms
Tiotropium
anticholinergic long acting inhibits M1 and M3 results in decreased cGMP–> bronchodilation ADR: blurred vision, dry mouth, nausea, urinary retention, tachycardia, CNS effects USES: maintenance of COPD
Acidinium bromide
anticholinergic long acting blocks M1 and M3 resulting in decreased cGMP —> bronchodilation ADR: blurred vision, dry mouth, nausea, urinary retention, tachycardia, CNS effects USES: maintenance of COPD
Umeclidinium bromide
anticholinergic long acting blocks M1 and M3 resulting in decreased cGMP –> bronchodilation ADR: blurred vision, dry mouth, nausea, urinary retention, tachycardia, CNS effects USES: maintenance of COPD
Theophylline
methylxanthine inhibits PDE and increase cAMP–> bronchodilation inflammatory cell regulator ADR: GI upset, tachyarrthymias, seizures, jitteriness USES: acute asthma; emphysema, chronic bronchitis
Beclomethasone
inhaled corticosteroid reduces inflammatory cells activation, recruitment, and infiltration decrease vascular permeability ADR: bone resorption, metabolism, skin thinning, candidiasis, GR
Budenoside
inhaled corticosteroid reduces inflammatory cells activation, recruitment, and infiltration decrease vascular permeability ADR: bone resorption, metabolism, candidiasis, GR
Fluticasone
inhaled corticosteroid reduces inflammatory cells activation, recruitment, and infiltration decrease vascular permeability ADR: bone resorption, metabolism, candidiasis, GR